The effect of minocycline on symptoms in schizophrenia: Results from a randomized controlled trial
- 1 April 2019
- journal article
- research article
- Published by Elsevier in Schizophrenia Research
- Vol. 206, 325-332
Abstract
No abstract availableKeywords
Funding Information
- Stanley Medical Research Institute
This publication has 25 references indexed in Scilit:
- The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis (BeneMin): a randomised, double-blind, placebo-controlled trialThe Lancet Psychiatry, 2018
- Minocycline as Add-On Treatment Decreases the Negative Symptoms of Schizophrenia; A Randomized Placebo-Controlled Clinical TrialRecent Patents on Inflammation & Allergy Drug Discovery, 2014
- Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatmentJournal of Psychopharmacology, 2012
- Why we should be wary of single-center trialsCritical Care Medicine, 2009
- Cognitive Effects of Antipsychotic Drugs in First-Episode Schizophrenia and Schizophreniform Disorder: A Randomized, Open-Label Clinical Trial (EUFEST)American Journal of Psychiatry, 2009
- Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS)Schizophrenia Research, 2008
- Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trialThe Lancet Neurology, 2007
- Minocycline and Cytoprotection: Shedding New Light on a Shadowy ControversyCurrent Drug Delivery, 2007
- Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's diseaseProceedings of the National Academy of Sciences, 2001
- The Positive and Negative Syndrome Scale (PANSS) for SchizophreniaSchizophrenia Bulletin, 1987